GlassScriptPhysician profile
Peter James Coutlakis
NPI 1528064482
$11,647.87
in general payments reported to CMS, 2019-2025
36 companies · $2,025 in 2025
The $2,025 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $448 · 2021: $1,738 · 2022: $2,118 · 2023: $2,496 · 2024: $1,877 · 2025: $2,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,196 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,195.67 |
| Education | $202.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,765.44 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $1,607.47 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,588.15 | 2019-2025 | Tremfya, Remicade, Simponi Aria |
| Pfizer INC. | $922.37 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $881.24 | 2019-2025 | |
| Ucb, INC. | $818.92 | 2019-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $696.28 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $470.43 | 2019-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $460.57 | 2021-2025 | Acthar |
| Glaxosmithkline, LLC. | $335.19 | 2019-2025 | Benlysta |
| Radius Health, INC. | $289.50 | 2023-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $250.86 | 2022-2025 | Saphnelo |
| Genentech USA, INC. | $209.02 | 2019-2025 | Actemra, Gazyva |
| Ani Pharmaceuticals, INC. | $189.22 | 2023-2025 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $122.24 | 2024-2025 | Idacio |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $94.44 | 2023-2025 | Lupkynis |
| Cumberland Pharmaceuticals, INC. | $91.22 | 2022 | |
| Genzyme Corporation | $89.77 | 2023-2025 | |
| Sobi, INC | $84.62 | 2023-2025 | |
| Celgene Corporation | $75.06 | 2019 | |
| Organon LLC | $71.32 | 2025 | Hadlima, Renflexis |
| Alexion Pharmaceuticals, INC. | $58.62 | 2019-2024 | Strensiq |
| Sandoz INC. | $58.45 | 2023-2024 | Hyrimoz |
| Mylan Institutional INC. | $53.48 | 2023 | Hulio |
| Horizon Therapeutics Plc | $51.50 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $45.66 | 2019 | |
| Kyowa Kirin, INC. | $45.42 | 2025 | |
| Mallinckrodt Enterprises LLC | $43.16 | 2019 | |
| Bioventus LLC | $37.42 | 2023-2024 | Durolane, Durolane |
| Pacira Pharmaceuticals Incorporated | $27.79 | 2023 | Zilretta |
| Celltrion USA INC. | $25.22 | 2023 | Yuflyma |
| Teva Pharmaceuticals USA, INC. | $23.39 | 2025 | Simlandi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.58 | 2022 | |
| Janssen Scientific Affairs, LLC | $17.54 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.56 | 2023 | Cyltezo |
| Ultragenyx Pharmaceutical INC. | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Coutlakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.